We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Arginine Feeding: a Novel Strategy to Improve Protein Metabolism in Cancer and the Response to Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00497380
Recruitment Status : Active, not recruiting
First Posted : July 6, 2007
Last Update Posted : April 19, 2017
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:
Muscle catabolism is a major problem in cancer patients undergoing surgery as it negatively affects post-operative recovery. Recent evidence exists that protein metabolic changes are already apparent in cancer before muscle wasting is being present. In line, patients with breast cancer, generally characterized by a normal nutritional status, were recently found to be arginine deficient. Arginine deficiency in cancer can be explained by: 1) Reduced arginine availability, due to exhaustion of endogenous (muscle) sources of arginine 2) Enhanced arginine catabolism, due to conversion of arginine by arginase, which is abundant in tumors. Protein is the most important endogenous source of arginine. Arginine deficiency will lead to a negative feedback loop in cachexia by promoting protein breakdown in an attempt to restore plasma arginine levels. We hypothesize that pre-operative arginine supplementation in breast cancer patients diminishes the occurrence of muscle wasting after surgery by 1) normalizing arginine availability pre-operatively, resulting in conservation of protein, 2) diminishing the catabolic effects of surgery by supplying exogenous arginine for the post-operative response, 3) enhancing the anabolic capacity to feeding through supplying substrate for protein synthesis.

Condition or disease Intervention/treatment
Protein Metabolism Dietary Supplement: Arginine

Detailed Description:

In the present proposal, the effects of surgery and cancer will be examined by comparing subjects undergoing breast surgery because of malignancy vs. prophylactic reasons (aim 1). Furthermore, the effects of one-week pre-operative protein feeding with or without enrichment with arginine on post-operative protein metabolism (aim 2) will be investigated in the cancer group. Variables of interest are: 1. Whole-body and skeletal muscle protein metabolism, whole body arginine turnover and de-novo arginine production rate, and the anabolic capacity to feeding(assessed by stable isotope methodology). 2. Body weight, muscle mass and functional status, score for well-being (assessed by Profile of Mood State and Mini Mental State).

In the present study, we propose that a nutritional supplement that is high in protein content and enhanced in arginine will be more effective than a typical commercial nutritional supplement in diminishing the catabolic effects of surgery in subjects with cancer, thereby optimizing their quality of life. If this is found to be the case, this would provide the basis for reformulating the nutritional composition in accord with the effects of cancer and surgery on protein metabolism.


Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 32 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Other
Official Title: Arginine Feeding: a Novel Strategy to Improve Protein Metabolism in Cancer and the Response to Surgery
Study Start Date : April 2009
Primary Completion Date : July 2012
Estimated Study Completion Date : February 2018

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: Arginine enriched nutrition Dietary Supplement: Arginine
Oral nutritional supplement
Placebo Comparator: Nutrition Dietary Supplement: Arginine
Oral nutritional supplement


Outcome Measures

Primary Outcome Measures :
  1. Net protein balance [ Time Frame: end of study ]

Secondary Outcome Measures :
  1. Arginine turnover [ Time Frame: end of study ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   30 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Cancer groups (for aims 1 and 2)

  1. Recently diagnosed (up to 4 weeks prior to treatment for cancer) with stage I, II or III invasive breast cancer
  2. Undergoing mastectomy
  3. Age greater than 30 years
  4. Ability to sign informed consent
  5. Good performance status defined by ECOG scale 0,1 or 2 (see CRF performance status)

Control group (for aim 1)

  1. Age greater than 30 years
  2. Undergoing prophylactic mastectomy
  3. Ability to sign informed consent
  4. Good performance status defined by ECOG scale 0,1 or 2 (see CRF performance status)

Exclusion Criteria:

All groups (aim 1 and 2)

  1. Body weight loss of greater than 10% in the past 3 months
  2. Previous anti-cancer therapy (e.g. chemotherapy or radiotherapy) or surgery less than 4 weeks prior to the experiment
  3. Diagnosed diabetes type I or II
  4. Untreated metabolic diseases including liver or renal disease
  5. Any documented autoimmune disease
  6. Use of corticosteroids, beta-antagonists or nitrovasodilators
  7. Use of supplements enriched with amino acids
  8. Presence of acute illness or metabolically unstable chronic illness
  9. Unstable heart disease requiring therapy or recent myocardial infarction (less than 1 year)
  10. Current alcohol or drug abuse (ETOH more than 2 servings per day)
  11. Allergy/intolerance to any of the ingredients of the study products
  12. Any other condition deemed by the PI and the study physician as exclusion or that interferes with proper conduct of the study/ safety of the patient.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00497380


Locations
United States, Arkansas
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States, 72205
Sponsors and Collaborators
Texas A&M University
Investigators
Principal Investigator: Nicolaas Deutz, M.D., Ph.D. University of Arkansas
More Information

Responsible Party: Marielle PKJ Engelen, PhD, PhD, Texas A&M University
ClinicalTrials.gov Identifier: NCT00497380     History of Changes
Other Study ID Numbers: 81167
First Posted: July 6, 2007    Key Record Dates
Last Update Posted: April 19, 2017
Last Verified: April 2017